Investor Presentaiton
Contract Manufacturing Business - Sterile Injectables and Non-Sterile
Products
Industry
Overview
(Injectables)
Injectable market stands at US$5.4bn and is expected to outpace the industry (ex API) by growing at a
CAGR of 4.7% between 2017-23F to reach US$7.1bn
Growth drivers include consolidation in injectable CDMO space, shortage of injectable drugs, vendor
consolidation and technical expertise for sterile injectable drugs
(US$bn)
59
Global Pharmaceutical CMO Industry Size
CAGR 12-17: 7.7%
CAGR 17-23F: 7.9%
63 67 73 79 85 92 100 109 117 125 134
43 46 50 55 60 66 72 79 87 94 102 110
2012
2013
■API
■ Solid
2018E
2019F
2020F
Injectable Other SDFN
2021F
2022F
2023F
Business
Overview
Products
Sterile injectables account for c.80% while non-sterile products account for the balance c.20% of CMO revenues
Deep and long-term relationships with our top 10 customers at least 10 years of business relationships with 6 of our top 10 customers. Serves 7 out of
the top 20 pharmaceutical companies globally based on revenue
➤ Fully integrated contract manufacturer of sterile injectables with in-house R&D capabilities - well positioned to become a leading, cost effective CMO
Full suite of services to our customers including supply chain support, lab testing services, regulatory submission support, manufacturing process
refinement and project management
USFDA approved manufacturing facilities located in Spokane, Washington and Montreal, Canada
Sterile Injectables
Freeze-dried (lyophilized) injectables, vial and ampoule liquid fills, Biologics, water for
injection diluents and Sterile ointment, creams and liquids
Currently produce vial ranges from two milliliters to 100 milliliters and batch sizes
ranging up to 2,000 litres
Capabilities to produce quantities for both large-scale commercial operations as well as
for clinical trials
Enhance and expand capacity
30% Capacity Expansion through following initiatives
☐
Capacity addition by operating one line 24X7
Strategy
effected in Spokane during Q3'FY19.
■ 24x7 shifts on another line from Q3'FY20
■ New Lyo equipment to increase capacity to be
commercialised in Q4'FY20
Achieve operational efficiencies
Focus on First Time Right
customer service and
increase product filling
yields
Reduce time cycle between
product releases
Non- sterile Products
Semi-solid dosage formulations, including antibiotic
ointments, dermatological creams and liquids
(syrups and suspensions)
Identify new customer targets
New customer targets for
ampoules, semi-solids and
non-sterile liquids
Focus on long term high
value contracts
Product portfolio extension
➤ Finding opportunities to strategically
extend our product portfolio
Investing in a brand new Ophthalmic
space in Montreal
Evaluating opportunities for new
product launches
Source: Frost & Sullivan - Independent Market Research on the Radiopharmaceutical Industry, US Radiopharmacy Chain, US Contract Manufacturing Organisation Industry, US Allergy Immuno Therapy Industry and the Global and US Generic Pharmaceutical Industry
JUBILANT
LIFESCIENCESView entire presentation